SavedAdd your journal

Journals / Haseki Tıp Bülteni / 2020 / Cilt: 58 - Sayı: 3

The Conversion Time of Cysts to Inactive form After Percutaneous Treatment of Hepatic Hydatid Disease and Predisposing Factors in This Process

Karaciğer Kist Hidatik Hastalığının Perkütan Tedavisi Sonrasında, Kistin İnaktif Formuna Dönüşüm Süresi ve Bu Süreci Etkileyen Faktörler

Bekir TURGUT
Fatih ÖNCÜ
Pages
286–292
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was a significant decrease in the inactivation time in patients who presented with complications (p=0.008).Conclusion: Patients who develop complications after percutaneous treatment and patients with longer catheterization exhibit shorter cyst inactivation time.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: This study aimed to evaluate the duration of cyst inactivation after percutaneous treatment of hepatic hydatid disease and the factors that may affect this process.Methods: Ultrasound follow-up records were evaluated, and the criteria for cyst inactivation were determined.
📊
Key Findings & Data:Percutaneous treatment technique, aspirated cyst content, complications, and duration of catheterization were listed.
💡
Conclusion & Impact:There was a significant decrease in the inactivation time in patients who presented with complications (p=0.008).Conclusion: Patients who develop complications after percutaneous treatment and patients with longer catheterization exhibit shorter cyst inactivation time.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: This study aimed to evaluate the duration of cyst inactivation after percutaneous treatment of hepatic hydatid disease and the factors that may affect this process.Methods: Ultrasound follow-up records were evaluated, and the criteria for cyst inactivation were determined. Cyst type, cyst size, and location were listed after scanning pre-treatment ultrasound reports. Percutaneous treatment technique, aspirated cyst content, complications, and duration of catheterization were listed. The time elapsed from percutaneous treatment to cyst inactivation was defined as inactivation time. Ultrasound follow-up period, cyst size at the last follow-up, and inactivation time were recorded.Results: A total of 116 patients were included in the study. The mean follow-up period after treatment was 1003.95±293.23 days. The mean inactivation time was 420.99±221.18 days. The size of the inactivated cysts decreased significantly compared to the pre-treatment cyst size (p=0.001). There was a positive correlation between cyst size and duration of catheterization (p=0.0001). The inactivation time decreased with increased duration of catheterization (p=0.001). There was a significant decrease in the inactivation time in patients who presented with complications (p=0.008).Conclusion: Patients who develop complications after percutaneous treatment and patients with longer catheterization exhibit shorter cyst inactivation time.

Özet

Amaç: Bu çalışmanın amacı karaciğer kist hidatik hastalığının perkütan tedavi sonrasında kist inaktivasyon süresini ve bu süreci etkileyebilecek faktörleri değerlendirmektir. Yöntemler: Takip ultrasonografi raporları değerlendirildi ve kist inaktivasyon kriterleri belirlendi. Tedavi öncesinde yapılmış olan ultrasonografi raporları taranarak kist tipi, kist boyutu ve lokalizasyonu listelendi. Uygulanan perkütan tedavi türü, kist içeriğinden gelen aspirat özelliği, komplikasyonlar, kateterizasyon süresi listelendi. Perkütan tedavi uygulama zamanından inaktif forma dönüşünceye kadar geçen süre, inaktivasyon süresi olarak tanımlandı. Ultrasonografi takip süresi, kistin son kontroldeki boyutu, inaktivasyon süresi kayıt edildi. Bulgular: Toplamda 116 hasta verileri çalışmaya dahil edildi. Tedavi sonrası ortalama takip süresi 1003,95±293,23 gün olmuştur. Ortalama inaktivasyon süresi 420,99±221,18 gün oldu. Tedavi öncesi kist boyutuna kıyasla inaktive olmuş kistlerde boyut anlamlı olarak azalmaktadır (p=0,001). Kist boyutu ile kateterizasyon süresi arasında pozitif bir korelasyon gözlendi (p=0,0001). Kateterizasyon süresi arttıkça inaktivasyon süresi azaldı (p=0,001). Komplikasyon gelişen hasta grubunda inaktivasyon süresinde anlamlı olarak azalma oldu (p=0,008). Sonuç: Perkütan tedavi sonrasında komplikasyon gelişen veya kateterizasyonun daha uzun süre olduğu hastalarda kist inaktivasyon süresi kısalmaktadır.

🔖

Cite This Article

TURGUT, B., ÖNCÜ, F. (2022). The Conversion Time of Cysts to Inactive form After Percutaneous Treatment of Hepatic Hydatid Disease and Predisposing Factors in This Process. Haseki Tıp Bülteni, Cilt: 58 - Sayı: 3, 286–292. https://ajindex.com/articles/535037

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Erol M, Yiğit Ö, Toksöz M, et al. Akciğer semptomları ile bulgu veren kist hidatikli olgularımızın değerlendirilmesi. Med Bull Haseki 2015;53:147-52
  2. Özer B, Kocakuşak A, Benek S, et al. Karaciğer kist hidatiğinde parsiyel kistektomi ve tüp drenaj tekniğinin diğer cerrahi metodlarla karşilaştirilmasi. Med Bull Haseki 2014;52:287-90
  3. Pedrosa I, Saíz A, Arrazola J, Ferreiro´s J, Pedrosa CS. Hydatid disease: radiologic and pathologic features and complications. RadioGraphics 2000;20:795-817
  4. Smego RA Jr, Sebanego P. Treatment options for hepatic cystic echinococcosis. Int J Infect Dis 2005;9:69-76
  5. Giorgio A, de Stefano G, Esposito V, et al. Longterm results of percutaneous treatment of hydatid liver cysts: a single center 17 years experience. Infection 2008;36:256-61
  6. Akhan O, Yildiz AE, Akinci D, Yildiz BD, Ciftci T. Is the adjuvant albendazole treatment really needed with PAIR in the management of liver hydatid cysts? A prospective, randomized trial with short-term follow-up results. Cardiovasc Intervent Radiol 2014;37:1568-74
  7. Kabaalioğlu A, Ceken K, Alimoglu E, Apaydin A. Percutaneous imaging-guided treatment of hydatid liver cysts: Do long-term results make it a first choice? European Journal of Radiology 2006;59:65-73
  8. Schipper HG, Lameris JS, van Delden OM, et al. Percutaneous evacuation (PEVAC) of multivesicular echinococcal cysts with or without cystobiliary fistulas which contain non-drainable material: first results of a modified PAIR method. Gut 2002;50:718-23
  9. Gabal AM, Khawaja FI, Mohammad GA. Modified PAIR technique for percutaneous treatment of high risk hydatid cysts. Cardiovasc Intervent Radiol 2005;28:200-8
  10. Akhan O, Salik AE, Ciftci T, Akinci D, Islim F, Akpinar B. Comparison of long-term results of percutaneous treatment techniques for hepatic cystic echinococcosis types 2 and 3b. AJR Am J Roentgenol 2017;208:878-84
  11. Popa AC, Akhan O, Petruţescu MS, et al. New options in the management of cystic echinococcosis - a single centre experience using minimally ınvasive techniques. Chirurgia (Bucur) 2018;113:486-96
  12. WHO Informal Working Group. International classification of US images in cystic echinococcosis for application in clinical and field epidemiological settings. Acta Trop 2003;85:253-61
  13. Wen H, Vuitton L, Tuxun T, et al. Echinococcosis: Advances in the 21st Century. Clin Microbiol Rev 2019;32:pii:e00075-18
  14. Akhan O, Gumus B, Akinci D, Karcaaltıncaba M, Ozmen M. Diagnosis and percutaneous